rituximab + cyclophosphamide + vincristine + prednisone

Rituximab + cyclophosphamide + vincristine + prednisone (commonly known as R-CVP) is a combination chemotherapy regimen used primarily for the treatment of indolent (slow-growing) non-Hodgkin lymphoma. The regimen includes four drugs with distinct mechanisms of action: - Rituximab is a monoclonal antibody targeting CD20 on B lymphocytes, leading to their destruction. - Cyclophosphamide is an alkylating agent that interferes with DNA replication and cell division. - Vincristine is a vinca alkaloid that inhibits microtubule formation, disrupting mitosis in cancer cells. - Prednisone is a corticosteroid that induces apoptosis in certain cancer cells and reduces inflammation. This combination works synergistically to kill cancer cells through multiple pathways and reduce tumor burden[1][2][7]. Each component drug has been individually approved by regulatory agencies for use in cancer therapy.

Brand names

None

Other names

rituximab + cyclophosphamide + vincristine sulfate + prednisoneR-CVP regimen